Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Ouabain Contributes to Kidney Damage in a Rat Model of Renal Ischemia-Reperfusion Injury.

Villa L, Buono R, Ferrandi M, Molinari I, Benigni F, Bettiga A, Colciago G, Ikehata M, Messaggio E, Rastaldi MP, Montorsi F, Salonia A, Manunta P.

Int J Mol Sci. 2016 Oct 14;17(10). pii: E1728.

2.

Personalized Therapy of Hypertension: the Past and the Future.

Manunta P, Ferrandi M, Cusi D, Ferrari P, Staessen J, Bianchi G.

Curr Hypertens Rep. 2016 Mar;18(3):24. doi: 10.1007/s11906-016-0632-y. Review.

PMID:
26915067
3.

Quantitative proteomics reveals novel therapeutic and diagnostic markers in hypertension.

Matafora V, Zagato L, Ferrandi M, Molinari I, Zerbini G, Casamassima N, Lanzani C, Delli Carpini S, Trepiccione F, Manunta P, Bachi A, Capasso G.

BBA Clin. 2014 Oct 22;2:79-87. doi: 10.1016/j.bbacli.2014.10.001. eCollection 2014 Dec.

4.

SIK1 localizes with nephrin in glomerular podocytes and its polymorphism predicts kidney injury.

Ferrandi M, Molinari I, Matafora V, Zerbini G, Trevisani F, Rastaldi MP, Simonini M, Giardino L, Ferrari P, Manunta P.

Hum Mol Genet. 2017 Feb 1;26(3):660. doi: 10.1093/hmg/ddu558. No abstract available.

PMID:
25392177
5.

Late sodium current (INaL) in pancreatic β-cells.

Rizzetto R, Rocchetti M, Sala L, Ronchi C, Villa A, Ferrandi M, Molinari I, Bertuzzi F, Zaza A.

Pflugers Arch. 2015 Aug;467(8):1757-68. doi: 10.1007/s00424-014-1613-0. Epub 2014 Sep 20.

PMID:
25236919
6.

Rostafuroxin protects from podocyte injury and proteinuria induced by adducin genetic variants and ouabain.

Ferrandi M, Molinari I, Rastaldi MP, Ferrari P, Bianchi G, Manunta P.

J Pharmacol Exp Ther. 2014 Nov;351(2):278-87. doi: 10.1124/jpet.114.217133. Epub 2014 Sep 3.

PMID:
25187430
7.

Lack of salt-inducible kinase 2 (SIK2) prevents the development of cardiac hypertrophy in response to chronic high-salt intake.

Popov S, Takemori H, Tokudome T, Mao Y, Otani K, Mochizuki N, Pires N, Pinho MJ, Franco-Cereceda A, Torielli L, Ferrandi M, Hamsten A, Soares-da-Silva P, Eriksson P, Bertorello AM, Brion L.

PLoS One. 2014 Apr 21;9(4):e95771. doi: 10.1371/journal.pone.0095771. eCollection 2014.

8.

SIK1 localizes with nephrin in glomerular podocytes and its polymorphism predicts kidney injury.

Ferrandi M, Molinari I, Matafora V, Zerbini G, Trevisani F, Rastaldi MP, Simonini M, Giardino L, Ferrari P, Manunta P.

Hum Mol Genet. 2014 Aug 15;23(16):4371-82. doi: 10.1093/hmg/ddu154. Epub 2014 Apr 3. Retraction in: Hum Mol Genet. 2017 Feb 1;26(3):660.

PMID:
24698975
9.

cGMP-dependent protein kinase 1 polymorphisms underlie renal sodium handling impairment.

Citterio L, Ferrandi M, Delli Carpini S, Simonini M, Kuznetsova T, Molinari I, Dell' Antonio G, Lanzani C, Merlino L, Brioni E, Staessen JA, Bianchi G, Manunta P.

Hypertension. 2013 Dec;62(6):1027-33. doi: 10.1161/HYPERTENSIONAHA.113.01628. Epub 2013 Sep 23.

PMID:
24060892
10.

Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition.

Ferrandi M, Barassi P, Tadini-Buoninsegni F, Bartolommei G, Molinari I, Tripodi MG, Reina C, Moncelli MR, Bianchi G, Ferrari P.

Br J Pharmacol. 2013 Aug;169(8):1849-61. doi: 10.1111/bph.12278.

11.

Preoperative endogenous ouabain predicts acute kidney injury in cardiac surgery patients.

Bignami E, Casamassima N, Frati E, Lanzani C, Corno L, Alfieri O, Gottlieb S, Simonini M, Shah KB, Mizzi A, Messaggio E, Zangrillo A, Ferrandi M, Ferrari P, Bianchi G, Hamlyn JM, Manunta P.

Crit Care Med. 2013 Mar;41(3):744-55. doi: 10.1097/CCM.0b013e3182741599.

12.
13.

NKCC2 is activated in Milan hypertensive rats contributing to the maintenance of salt-sensitive hypertension.

Carmosino M, Rizzo F, Ferrari P, Torielli L, Ferrandi M, Bianchi G, Svelto M, Valenti G.

Pflugers Arch. 2011 Aug;462(2):281-91. doi: 10.1007/s00424-011-0967-9. Epub 2011 May 7.

PMID:
21553016
14.

Mutation in the beta adducin subunit causes tissue-specific damage to myogenic tone.

Sonoyama K, Greenstein AS, Micheletti R, Ferrari P, Schiavone A, Aghamohammadzadeh R, Withers SB, Tripodi G, Ferrandi M, Heagerty AM.

J Hypertens. 2011 Mar;29(3):466-74. doi: 10.1097/HJH.0b013e328341e1a1.

PMID:
21150638
15.

Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies.

Lanzani C, Citterio L, Glorioso N, Manunta P, Tripodi G, Salvi E, Carpini SD, Ferrandi M, Messaggio E, Staessen JA, Cusi D, Macciardi F, Argiolas G, Valentini G, Ferrari P, Bianchi G.

Sci Transl Med. 2010 Nov 24;2(59):59ra87. doi: 10.1126/scitranslmed.3001814.

16.

Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 1: experimental studies.

Ferrandi M, Molinari I, Torielli L, Padoani G, Salardi S, Rastaldi MP, Ferrari P, Bianchi G.

Sci Transl Med. 2010 Nov 24;2(59):59ra86. doi: 10.1126/scitranslmed.3001815.

17.

alpha- and beta-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy.

Ferrandi M, Cusi D, Molinari I, Del Vecchio L, Barlassina C, Rastaldi MP, Schena FP, Macciardi F, Marcantoni C, Roccatello D, Peters LL, Armelloni S, Min L, Giardino L, Mattinzoli D, Camisasca C, Palazzo F, Manunta P, Ferrari P, Bianchi G.

J Mol Med (Berl). 2010 Feb;88(2):203-17. doi: 10.1007/s00109-009-0549-x. Epub 2009 Oct 17.

18.

Endogenous ouabain in cardiovascular function and disease.

Manunta P, Ferrandi M, Bianchi G, Hamlyn JM.

J Hypertens. 2009 Jan;27(1):9-18. doi: 10.1097/HJH.0b013e32831cf2c6. Review.

PMID:
19050443
19.

Glomerular barrier dysfunction in glomerulosclerosis- resistant Milan rats with experimental diabetes: the role of renal haemodynamics.

Pugliese G, Ricci C, Iacobini C, Menini S, Fioretto P, Ferrandi M, Giardino LA, Armelloni S, Mattinzoli D, Rastaldi MP, Pugliese F.

J Pathol. 2007 Oct;213(2):210-8. Erratum in: J Pathol. 2007 Oct;213(2):218.

PMID:
17768702
20.

Ouabain-dependent signaling in caveolae as a novel therapeutic target for hypertension.

Ferrandi M, Molinari I, Bianchi G, Ferrari P.

Cell Mol Biol (Noisy-le-grand). 2006 Dec 30;52(8):15-8. Review.

PMID:
17535730
21.

Adducin polymorphisms and the treatment of hypertension.

Manunta P, Citterio L, Lanzani C, Ferrandi M.

Pharmacogenomics. 2007 May;8(5):465-72. Review.

PMID:
17465710
22.

Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure.

Micheletti R, Palazzo F, Barassi P, Giacalone G, Ferrandi M, Schiavone A, Moro B, Parodi O, Ferrari P, Bianchi G.

Am J Cardiol. 2007 Jan 22;99(2A):24A-32A. Epub 2006 Sep 25.

PMID:
17239701
23.

Targeting Ouabain- and Adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach.

Ferrari P, Ferrandi M, Valentini G, Manunta P, Bianchi G.

Med Hypotheses. 2007;68(6):1307-14. Epub 2006 Nov 9.

PMID:
17097240
24.

A new antihypertensive agent that antagonizes the prohypertensive effect of endogenous ouabain and adducin.

Manunta P, Ferrandi M, Messaggio E, Ferrari P.

Cardiovasc Hematol Agents Med Chem. 2006 Jan;4(1):61-6. Review.

PMID:
16529550
25.

Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension.

Ferrari P, Ferrandi M, Valentini G, Bianchi G.

Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R529-35. Review.

26.

Cardiac glycosides and cardiomyopathy.

Manunta P, Ferrandi M.

Hypertension. 2006 Mar;47(3):343-4. Epub 2006 Feb 6. No abstract available.

PMID:
16461849
27.

Ouabain antagonists as antihypertensive agents.

Ferrandi M, Barassi P, Molinari I, Torielli L, Tripodi G, Minotti E, Bianchi G, Ferrari P.

Curr Pharm Des. 2005;11(25):3301-5. Review.

PMID:
16250857
28.

The endogenous ouabain: molecular basis of its role in hypertension and cardiovascular complications.

Ferrandi M, Manunta P, Ferrari P, Bianchi G.

Front Biosci. 2005 Sep 1;10:2472-7. Review.

PMID:
15970509
29.

Effect of Add1 gene transfer on blood pressure in reciprocal congenic strains of Milan rats.

Tripodi G, Florio M, Ferrandi M, Modica R, Zimdahl H, Hubner N, Ferrari P, Bianchi G.

Biochem Biophys Res Commun. 2004 Nov 12;324(2):562-8.

PMID:
15474463
30.

Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238.

Ferrandi M, Molinari I, Barassi P, Minotti E, Bianchi G, Ferrari P.

J Biol Chem. 2004 Aug 6;279(32):33306-14. Epub 2004 May 25.

31.

Different effects of marinobufagenin and endogenous ouabain.

Manunta P, Ferrandi M.

J Hypertens. 2004 Feb;22(2):257-9. Review. No abstract available.

PMID:
15076181
32.

Antihypertensive compounds that modulate the Na-K pump.

Ferrari P, Ferrandi M, Torielli L, Barassi P, Tripodi G, Minotti E, Molinari I, Melloni P, Bianchi G.

Ann N Y Acad Sci. 2003 Apr;986:694-701. Review.

PMID:
12763920
33.

PST 2238: a new antihypertensive compound that modulates renal Na-K pump function without diuretic activity in Milan hypertensive rats.

Ferrandi M, Barassi P, Minotti E, Duzzi L, Molinari I, Bianchi G, Ferrari P.

J Cardiovasc Pharmacol. 2002 Dec;40(6):881-9.

PMID:
12451321
34.

Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension.

Manunta P, Messaggio E, Ballabeni C, Sciarrone MT, Lanzani C, Ferrandi M, Hamlyn JM, Cusi D, Galletti F, Bianchi G; Salt Sensitivity Study Group of the Italian Society of Hypertension.

Hypertension. 2001 Aug;38(2):198-203.

PMID:
11509476
35.

Endogenous ouabain and hemodynamic and left ventricular geometric patterns in essential hypertension.

Pierdomenico SD, Bucci A, Manunta P, Rivera R, Ferrandi M, Hamlyn JM, Lapenna D, Cuccurullo F, Mezzetti A.

Am J Hypertens. 2001 Jan;14(1):44-50.

PMID:
11206678
36.

PST 2238: a new antihypertensive compound that modulates the Na-K pump 'in vivo' and 'in vitro'.

Ferrari P, Ferrandi M, Torielli L, Tripodi G, Bianchi G.

Hypertens Res. 2000 Sep;23 Suppl:S15-9. Review.

37.

Ouabain-like factor: is this the natriuretic hormone?

Ferrandi M, Manunta P.

Curr Opin Nephrol Hypertens. 2000 Mar;9(2):165-71. Review.

PMID:
10757222
38.

Genetic mechanisms underlying the regulation of urinary sodium excretion and arterial blood pressure: the role of adducin.

Ferrandi M, Bianchi G.

Acta Physiol Scand. 2000 Jan;168(1):187-93. Review. No abstract available.

PMID:
10691799
39.

Evidence for an interaction between adducin and Na(+)-K(+)-ATPase: relation to genetic hypertension.

Ferrandi M, Salardi S, Tripodi G, Barassi P, Rivera R, Manunta P, Goldshleger R, Ferrari P, Bianchi G, Karlish SJ.

Am J Physiol. 1999 Oct;277(4):H1338-49. doi: 10.1152/ajpheart.1999.277.4.H1338.

PMID:
10516168
40.

Left ventricular mass, stroke volume, and ouabain-like factor in essential hypertension.

Manunta P, Stella P, Rivera R, Ciurlino D, Cusi D, Ferrandi M, Hamlyn JM, Bianchi G.

Hypertension. 1999 Sep;34(3):450-6.

PMID:
10489392
41.

PST 2238: A new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension.

Ferrari P, Ferrandi M, Tripodi G, Torielli L, Padoani G, Minotti E, Melloni P, Bianchi G.

J Pharmacol Exp Ther. 1999 Mar;288(3):1074-83.

PMID:
10027844
42.

Role of the ouabain-like factor and Na-K pump in rat and human genetic hypertension.

Ferrandi M, Manunta P, Rivera R, Bianchi G, Ferrari P.

Clin Exp Hypertens. 1998 Jul-Aug;20(5-6):629-39. Review.

PMID:
9682919
43.

PST2238: a new antihypertensive compound that antagonizes the long-term pressor effect of ouabain.

Ferrari P, Torielli L, Ferrandi M, Padoani G, Duzzi L, Florio M, Conti F, Melloni P, Vesci L, Corsico N, Bianchi G.

J Pharmacol Exp Ther. 1998 Apr;285(1):83-94.

PMID:
9535997
44.

Ouabain-like factor quantification in mammalian tissues and plasma: comparison of two independent assays.

Ferrandi M, Manunta P, Balzan S, Hamlyn JM, Bianchi G, Ferrari P.

Hypertension. 1997 Oct;30(4):886-96.

PMID:
9336389
45.

Renal Na,K-ATPase in genetic hypertension.

Ferrandi M, Tripodi G, Salardi S, Florio M, Modica R, Barassi P, Parenti P, Shainskaya A, Karlish S, Bianchi G, Ferrari P.

Hypertension. 1996 Dec;28(6):1018-25.

PMID:
8952591
46.

Age-dependency and dietary influence on the hypothalamic ouabain-like factor in Milan hypertensive rats.

Ferrandi M, Minotti E, Florio M, Bianchi G, Ferrari P.

J Hypertens. 1995 Dec;13(12 Pt 2):1571-4.

PMID:
8903611
47.

Two point mutations within the adducin genes are involved in blood pressure variation.

Bianchi G, Tripodi G, Casari G, Salardi S, Barber BR, Garcia R, Leoni P, Torielli L, Cusi D, Ferrandi M, et al.

Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3999-4003.

48.

Effect of canrenone and hydrochlorothiazide on the development of hypertension in rat models of genetic hypertension.

Ferrari P, Ferrandi M, Minotti E, Duzzi L, Bianchi G.

J Hypertens Suppl. 1993 Dec;11(5):S330-1. No abstract available.

PMID:
8158408
49.

Characteristics of a ouabain-like factor from Milan hypertensive rats.

Ferrandi M, Minotti E, Salardi S, Florio M, Bianchi G, Ferrari P.

J Cardiovasc Pharmacol. 1993;22 Suppl 2:S75-8.

PMID:
7508036
50.

Ouabainlike factor in Milan hypertensive rats.

Ferrandi M, Minotti E, Salardi S, Florio M, Bianchi G, Ferrari P.

Am J Physiol. 1992 Oct;263(4 Pt 2):F739-48.

PMID:
1329560

Supplemental Content

Loading ...
Support Center